WO2022123505A1 - Quantitative immunohistochemical antigen determination method - Google Patents
Quantitative immunohistochemical antigen determination method Download PDFInfo
- Publication number
- WO2022123505A1 WO2022123505A1 PCT/IB2021/061547 IB2021061547W WO2022123505A1 WO 2022123505 A1 WO2022123505 A1 WO 2022123505A1 IB 2021061547 W IB2021061547 W IB 2021061547W WO 2022123505 A1 WO2022123505 A1 WO 2022123505A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- substrate
- antigen
- sections
- peroxidase
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 36
- 102000036639 antigens Human genes 0.000 title claims abstract description 35
- 108091007433 antigens Proteins 0.000 title claims abstract description 35
- 230000002055 immunohistochemical effect Effects 0.000 title claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 238000002798 spectrophotometry method Methods 0.000 claims abstract description 9
- 238000005406 washing Methods 0.000 claims abstract description 9
- 238000004737 colorimetric analysis Methods 0.000 claims abstract description 8
- 239000002771 cell marker Substances 0.000 claims abstract 3
- 210000001519 tissue Anatomy 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102000003992 Peroxidases Human genes 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 11
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 11
- 102000053602 DNA Human genes 0.000 claims description 6
- 102000011782 Keratins Human genes 0.000 claims description 6
- 108010076876 Keratins Proteins 0.000 claims description 6
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 108010008707 Mucin-1 Proteins 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- CPOBTYJRKAJERX-UHFFFAOYSA-N 3-ethyl-n-[(3-ethyl-1,3-benzothiazol-2-ylidene)amino]-1,3-benzothiazol-2-imine Chemical compound S1C2=CC=CC=C2N(CC)C1=NN=C1SC2=CC=CC=C2N1CC CPOBTYJRKAJERX-UHFFFAOYSA-N 0.000 claims description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical group C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- 102000007298 Mucin-1 Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 238000003364 immunohistochemistry Methods 0.000 description 12
- 102000008096 B7-H1 Antigen Human genes 0.000 description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 description 10
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical group C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000012151 immunohistochemical method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 102100022183 E3 ubiquitin-protein ligase MIB1 Human genes 0.000 description 1
- 108700036009 EC 3.4.21.64 Proteins 0.000 description 1
- 101000973503 Homo sapiens E3 ubiquitin-protein ligase MIB1 Proteins 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 241001602730 Monza Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- -1 TMB) Chemical compound 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- diaminobenzidine acts as acceptor of the oxygen released following the reaction of the peroxidase enzyme on hydrogen peroxide.
- Diaminobenzidine is currently used in immunohistochemistry (IHC) because, following oxidation, it gives rise to a brownish- black insoluble product that precipitates on the site of production and labels the cells containing the antigen.
- H4C is therefore a powerful tool for pathological diagnosis; however, it has intrinsic limitations in the case of tailored treatments, which increasingly often require reliance on the quantitative measurement of biomarkers.
- Customised treatments require a solid stratification of patients into prognostic and predictive categories based on reliable information of various kinds: clinical information and radiological, pathological and molecular tests. It is often necessary to combine several test procedures to obtain the optimum results.
- Protein biomarkers, measured in pathological tissues, are important because they represent molecules that constitute the final result of genetic anomalies and metabolic disorders, and can become the targets of treatment.
- the total DNA present in a histological section can be evaluated by lysing the section (e.g. with peptidase K) and then reading the amount of DNA on the basis of the spectrophotometric absorption.
- Tissue cancers are currently tested for expression of PD-L1 (Programmed Death- Ligand 1) in order to devise the therapeutic approach. It has been observed that in immune “checkpoints” PD1-PDL1 there is a mechanism that blocks the immune response, and that expression of PD-L1 is correlated with immune evasion by tumour tissues. Treatment with anti-PD-Ll antibodies can have the effect of controlling tumour growth in tumours that express said marker, and the therapeutic effect observed is correlated with the intensity of expression. PD-L1 is therefore tested for in histological sections, using immunohistochemical methods. The evaluation of intensity of expression is reported as the percentage of positive cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Disclosed is a method of quantitative immunohi stochemi cal determination of tissue antigens that comprises: a) Placing histological preparations in contact with an anti-antigen antibody and then with an anti -antibody antibody labelled with a specific enzyme for a substrate detectable by colorimetry; b) Developing the preparation with a substrate that gives rise to a soluble product determinable by spectrophotometry, and reading of a first signal X; c) Removing the anti-antigen and anti -antibody antibodies by washing; d) Placing the washed preparation in contact with a second anti-cell marker antibody, and then with an anti -antibody antibody labelled with a specific enzyme for a substrate detectable by colorimetry; e) Developing the preparation with a substrate that gives rise to a product determinable by spectrophotometry, and reading of a second signal Y; f) Determining index X/Y x 100.
Description
QUANTITATIVE IMMUNOHISTOCHEMICAL ANTIGEN DETERMINATION
METHOD
The invention relates to a method of quantitative immunohistochemical determination of tissue antigens.
Prior art
The immunohistochemical technique on histological sections enables cell antigens to be localised in tissues, giving rise to a coloured reaction visible under the microscope. Said procedure is currently used for diagnostic purposes, finalized both to morphological and functional tissue characterization, and to determine the therapeutic approach. The presence and amount of markers, such as receptors in particular, is the prerequisite that predicts the response to targeted treatments. Hence the need to “quantify” immunohistochemical staining. Said quantitation is currently expressed with a visual evaluation of the relative frequency of specifically stained cells (1+, 2+, 3+), with highly detailed counts (e.g. no. of positive cells in 1000 cells) and, most recently, with computerised image analysis techniques. Said procedures are not only complex, but also poorly replicable as they are liable to subjective interpretations. Immunohistochemical methods, which were developed to enable antigens to be localised in cells and tissues, are based on the antigen-antibody bond, leading to a stained reaction giving a microscopic display of the binding site. The display of the reaction, initially based on fluorescent stains (hence the term “immunofluorescence”), was subsequently developed by using antibodies conjugated with enzymes, in particular horseradish peroxidase, and the reaction site is then displayed with an enzyme-histochemical reaction giving rise to an insoluble coloured product. The main reagent used for this purpose is diaminobenzidine, which acts as acceptor of the oxygen released following the reaction of the peroxidase enzyme on hydrogen peroxide. Diaminobenzidine is currently used in immunohistochemistry (IHC) because, following oxidation, it gives rise to a brownish- black insoluble product that precipitates on the site of production and labels the cells
containing the antigen. The techniques have evolved with time, and other enzymes (alkaline phosphatase, glucose oxidase and beta-galactosidase) have been used as an alternative to peroxidase; in all such cases other substrates were used, all of which have the common property of giving rise to insoluble coloured products, that microscopically label the various cells containing the antigen tested for.
This type of approach, based on identification of particular cell differentiations and localisation of antigens labelling differentiating lines, led to considerable progress in histological and cytological interpretation and had considerable diagnostic repercussions, especially in the oncological field, allowing the various types of tumour to be characterised not only on a morphological and structural basis, but also on a functional and differentiating basis. A further, significant development took place when it was observed that immunohistochemical reactions could also be conducted on tissue sections fixed in formalin and embedded in paraffin, because physicochemical treatments, in particular heating of sections, gave rise to “antigen retrieval”. It was also observed that not only the presence of a given antigen, but also its amount of expression, allowed the appropriate pharmacological treatment to be devised. In particular, in breast cancer, it was observed that the amount of expression of the HER2 receptor was the factor that allowed the response of a tumour to targeted anti-HER2 treatments to be predicted (Taylor, 1993; Grube, 2004; Taylor and Levenson, 2006; Taylor, 2014). In currently approved protocols, treatment with anti-HER.2 antibodies is reserved for cases wherein HER2 expression is highest (known as 3+), whereas the treatment is ineffective if expression is lower (value 0, 1, 2+). The presence, and above all the amount, of expression of different antigens (“markers”) represents a crucial factor that influences the use of specific procedures in the ambit of tailored treatments (Lehr et al., 2001; Hatanaka et al., 2001; Rhodes et al., 2002). At present, conventional H4C is therefore a powerful tool for pathological diagnosis; however, it has intrinsic limitations in the case of tailored treatments, which increasingly often require reliance on the quantitative measurement of biomarkers. Customised treatments require a solid stratification of patients into prognostic and predictive
categories based on reliable information of various kinds: clinical information and radiological, pathological and molecular tests. It is often necessary to combine several test procedures to obtain the optimum results. Protein biomarkers, measured in pathological tissues, are important because they represent molecules that constitute the final result of genetic anomalies and metabolic disorders, and can become the targets of treatment. The need to determine the amount of localised antigen using immunohistochemistry as a tool for quantifying protein biomarkers in tissue is currently pursued, because clinical oncologists require this information to devise the treatment approach (Becker, 1993; Cross, 2001; Seidal et al., 2001). Determining the amount of stain deposited on the sections by microscopic examination is subjective and poorly replicable, which conflicts with the need for highly reliable data in order to make decisions on the adoption of specific treatments. Numerous attempts have been made using manual counts of positive cells compared with a fixed number (100 or 1000) of the total cells, or using image analysis on electronically acquired (“scanned”) preparations, but even such approach has given somewhat unreliable results, due to both technical difficulties and difficulty of interpretation (Cross, 2001; Di Cataldo et al., 2012; Linden et al., 2015; Laurinavicius et al., 2016). The various methods, options and limitations of said procedures were illustrated by Taylor (2014). The amount of the problems and opportunities arising in quantitative H4C is very broad, because reaction times and temperature, as well as the thickness of the sections, can affect the intensity of the staining. Moreover, a true reference standard for calibrating and checking the analytical accuracy of the test is difficult to obtain with IHC. A possible method could involve using a quantitative internal reference standard based on double staining in IHC to compare the amount of an intrinsic tissue. Moreover, although the bright-field chromogen produced in IHC (generally DAB) clearly delineates the tissue architecture and is preferred by pathologists, immunofluorescence-based techniques are more suitable for detection of the multiplex antigen than for true quantitation. As IHC does not provide data on the real protein concentrations, only information about the extent of the positive areas and cells, it derives
that the data supplied are highly subjective and poorly replicable. Finally, it should be added that production of the stained product (oxidised DAB) deposited on the reaction site does not increase linearly with the reaction time, but reaches a plateau, after which the accumulated stain prevents further development of the reaction by steric impact. Finally, it should be specified that integral cells or whole nuclei are not evaluated in histological sections, but sections thereof, which may be equatorial, but are more often only tangential (the cells have a variable diameter, ranging between about 7 and 15 microns, while the sections have a thickness of about 4 microns). Hence the difficulty, and perhaps impossibility, of measuring the percentages of cells or nuclei positive for a given reaction, compared with the rest of the negative cells or nuclei.
Description of the invention
An innovative process of antigen quantitation has now been found, characterised by the development of histological sections processed by immunohistochemistry by means of a reaction with a coloured product quantifiable on the basis of spectrophotometric absorption. The value obtained from the spectrophotometer reading is calculated as a ratio of a value obtained by a second immunohistochemical procedure on the same section, by labelling a general indicator of the amount of cells or reference structures (such as epithelial cells or total nuclei present in the same section).
The invention therefore provides a method of quantitative immunohistochemical determination of tissue antigens that comprises: a) Placing the histological preparation in contact with an anti-antigen tissue antibody of diagnostic interest, and then with an anti-antibody antibody labelled with a specific enzyme for a substrate detectable by colorimetry; b) Developing the preparation with a substrate that gives rise to a soluble product determinable by spectrophotometry, and reading of a first signal X; c) Removing the anti-antigen and anti-antibody antibodies after step b) by washing to remove the specific binding; d) Placing the washed preparation in contact with a second anti-epithelial cell or
anti-nuclear marker antibody, and then with an anti-antibody antibody labelled with a specific enzyme for a substrate detectable by colorimetry; e) Developing the preparation with a substrate that gives rise to a product determinable by spectrophotometry, and reading of a second signal Y; f) Determining index X/Y x 100.
The method according to the invention therefore provides two values, relating to the same section: the amount of reference marker, and the amount of the reference cells (total cells. The marker/cell ratio will indicate, in numerical values, the percentage of cells positive for the marker and the intensity of expression thereof. The result will therefore be an objective numerical value that measures the expression of a given antigen of interest, as a ratio of the total number of tumour cells. Similarly, the percentage of cells or tissue components (nuclei, connective tissue, blood vessels or inflammatory infiltrate) can be measured in relation to a reference component (amount of DNA or cytoplasm or connective tissue present, using suitable antibodies).
The specific enzyme for a substrate detectable by colorimetry is preferably a peroxidase, such as horseradish peroxidase.
Examples of soluble substrates for peroxidase include tetramethylbenzidine (3, 3', 5, 5' tetramethylbenzidine, TMB), ABTS (2,2'-azino-di[3-ethylbenzothiazoline] sulphonate) and OPD (o-phenylenediamine) which give a blueish or greenish soluble product that accumulates in the reaction medium according to the reaction time and the amount of peroxidase present. Said reaction enables the amount of antigen present to be evaluated indirectly by spectrophotometric measurement of the amount of colour produced.
As an alternative to peroxidase, other enzymes, such as alkaline phosphatase, glucose-oxidase and beta-galactosidase, can be used, subsequently employing soluble coloured reagents evaluatable with spectrophotometry or fluorescent products, also detectable with a spectrophotometer. The development can also be performed with reagents that give rise to coloured products which are water-insoluble but subsequently
solubilisable in solvents, and can therefore always be red with the spectrophotometer.
The method according to the invention is suitable for quantitation of any tissue antigen of interest for diagnostic, prognostic and therapeutic purposes. A particularly interesting field of application relates to tumour antigens such as HER2, Ki67 and PD-L1. Examples of cell markers usable according to the invention are cytokeratin, EMA (Epithelial Membrane Antigen) and dsDNA.
By following similar procedures, it will be possible to use the quantitative analysis described herein to evaluate different cell types present in the same section comparatively (e.g. the ratio between T lymphocytes and B lymphocytes), each cell type being identified by specific markers.
The method according to the invention can be performed not only on the same section but also on parallel sections, such as parallel serial sections.
The results can be read not only with conventional spectrophotometry techniques, but also by scanning and total byte weight of the scanned image.
If desired, the total amount of proteins present in a histological section can be evaluated by lysing it with Lysis Buffer or SDS (sodium dodecyl sulphate) elution, and measuring the proteins in the lysate by Lowry reaction or biuret reaction.
The total DNA present in a histological section can be evaluated by lysing the section (e.g. with peptidase K) and then reading the amount of DNA on the basis of the spectrophotometric absorption.
Detailed description of the invention
For example, to establish the percentage of neoplastic cells positive for antigen X (e.g. HER2) in a breast cancer, and also the intensity of expression of said antigen, the immunohistochemical reaction for the antigen can be performed with an anti-antigen X primary antibody, followed by a peroxidase-labelled antibody, against the primary antibody. At this point, instead of developing with DAB (as routinely performed), the histological section is exposed to a fixed amount (e.g. 0.5 ml) of TMB-based reagent. After a set time (e.g. 10 min.), the development reagent is taken up and the intensity of
reaction evaluated spectrophotometrically at the established wavelength to obtain a numerical value (“value X”). The resulting numerical value is not significant per se. However, it acquires a useful value if related to the basal value determinable by conducting steps c)-f) of the method according to the invention. In particular, the histological section used in steps a) and b) is washed in saline solution, then treated with acid solution at pH 2.2 for 10 min, to entirely remove the antibodies bonded in the first reaction. The section undergoes a new immunohistochemical reaction, using antibodies against antigen Y (e.g. anti-keratin, which stains all the epithelial cells of the carcinoma listed above). This will be followed by peroxidase-labelled antibodies against the primary antibody. By developing the reaction with TMB as described above, and evaluating the intensity of the reaction with the spectrophotometer, a numerical value (“value Y”) is obtained. By calculating the ratio between value X and value Y (X/Y x 100) a reference value (“Index”) is obtained, which indicates the corresponding number of tumour cells expressing antigen X and the intensity of said expression, in relation to the total number of tumour cells. Said value will be independent of the width or thickness of the section. It will thus be possible to provide to the clinicians numerical values of all the targets that indicate possibilities of a therapeutic response.
In order to expose the histological sections (on a slide) to the correct amount of TMB medium for incubation, the use of glass or plasticwells, slightly longer than a histological slide, is preferred, e.g. width 25 to 27 mm, length 75 to 78 mm and height 1 to 5 mm, preferably 25 x 76 mm, with a depth of about 3 mm. Said wellsenable the slides to be incubated face down, thereby directly exposing the histological sections to the incubation medium. At the end of incubation, the slide is removed and the medium remains in thewell, from which it can be removed for measurement. The wells wherein the preparations are incubated can also be vertical, with a width of 1 to 3 mm and height of 50 to 75 mm. Incubation can also be performed by placing the incubation medium in contact with the histological sections, over or under the slide or between the histological slide and a coverslip.
The following examples illustrate the invention in greater detail.
Example 1
On immunohistochemical staining for HER2, on the basis of the extent and intensity of the reaction for HER2 on the tumour cell membrane, cases 19584 and 20926 were scored as 3+, case 20574 as 2+ and case 18980 as 1+, while cases 18583 and 24520 were wholly negative (o+). 4 micron thick histological sections were taken from each case, and mounted on histological slides.
The sections were processed immunohistochemically, after paraffin removal, using a Ventana automated apparatus (Ventana BenchMark AutoStainer, Ventana Medical Systems, USA). After antigen retrieval treatment with Cell Conditioning 1 (CC1, slightly basic; Ventana) for 36 minutes at 95°C, the sections were incubated with 4B5 rabbit antibody (Roche). After washing, the sections were treated with peroxidase- labelled anti-rabbit immunoglobulin antibody (Ultraview detection kit, Ventana).
The sections did not undergo the usual routine DAB staining, but were placed in phosphate-buffered saline solution (PBS) and processed with reagent containing 3, 3’, 5, 5’- tetramethylbenzidine (TMB), liquid substrate for ELISA (manufactured by Sigma, Milan). We used glass or plastic wells with dimensions suitable to contain a histological slide (2.5 x 7.5 cm) and a depth of 3 mm. We placed 0.5 ml of TMB reagent in saidwell , then immersed the histological section face down, ensuring that the section was fully in contact with the reagent. The reaction was developed (in the dark) for 10 min. at room temperature, and the section was then replaced in PBS. The reaction medium was collected, mixed in equal parts with blocking liquid (pH 2), and processed for microspectrophotometer reading. The histological sections, after washing in PBS, were immersed in acid solution (0.01N HC1, pH 2.2) for 10 min. at room temperature, then
washed again in PBS and processed immunohistochemically in a Ventana apparatus as specified above. After treatment with protease 1 for 4 min, the sections were treated with anti-PanCytokeratin mouse antibody (AE1/AE3/PCK26, Roche), then with a reagent designed to detect mouse immunoglobulins (Ultraview detection kit, Ventana). The sections, collected in PBS, were treated with TMB as described above, to measure the amount of peroxidase and therefore, indirectly, the amount of cytokeratin present in the sections, as an indicator of the epithelial cells present. After the reaction, the TMB reagent was processed for reading on the spectrophotometer. After development of the reaction in TMB, the sections were washed in PBS, then stained for peroxidase with diaminobenzidine (DAB) according to the ordinary immunohistochemical staining process. This enabled the correctness of the reaction to be checked visually, because uniform cytoplasmic staining of all breast cancer epithelial cells is observed. The absence of tumour cell membrane staining confirmed the removal (by acid solution) of the anti- HER2 antibodies bonded during the first step of the process.
The individual values are obviously not significant per se. However, when the percentage ratio HER2/cytokeratin X 100 is calculated for the individual cases, the following values are obtained, namely a HER2/ CK index:
0,25/2,52 x 100= 9,90%
0,52/3,20 x 100= 16,00%
1 ,32/3,10 x 100= 42,50%
0,12/2,83 x 100= 4,20%
It was accordingly found that the two cases which, on immunohistochemical reading, had been evaluated as 3+ (cases 19584 and 20926), had the highest values (62 and 95%), case 20574 (2+) had an intermediate value (46%) and case 18980 (1+) a value of 16%, while cases 18583 and 24520 (o+) had the smallest percentage values (9 and 4%).
Example 2
An immunohistochemical method has been designed to detect the DNA present in a histological section using an anti-double-stranded DNA mouse monoclonal antibody (Double Stranded DNA Monoclonal Antibody (AE-2) Catalogue number: MAI 35346; manufacturer Thermo Fisher Scientific, Monza, Italy). Using a suitable dilution of the antibody in buffered saline solution (PBS) and employing immunohistochemical methods with peroxidase-labelled anti-mouse IG antibodies (Ultraview detection kit, Ventana), and developing the immunohistochemical reaction with diaminobenzidine (DAB), staining of all the nuclei present in the section was observed. Two cases of breast cancer were selected. After fixing in buffered formalin and embedding in paraffin, the sections were stained with antibodies against Ki67, a nuclear marker expressed in proliferating cells. In said immunohistochemical reaction, the number of tumour cell nuclei positive for Ki67 is taken as reference number to indicate the proliferative activity in the tumour. In these two cases (case A and case B), the number of positive Ki67 cells was calculated (optical evaluation) as 10% in case A, and 80% in case B. Sections of the two cases were processed immunohistochemically, after paraffin removal, using a Ventana automated apparatus (Ventana BenchMark AutoStainer, Ventana Medical Systems, USA). After antigen retrieval treatment with Cell Conditioning 1 (CC1, slightly basic; Ventana) for 36
minutes at 95°C, the sections were incubated with anti-Ki67 MIB1 mouse antibody (Roche). After washing, the sections were treated with peroxidase-labelled anti-mouse immunoglobulin antibody (Ultraview detection kit, Ventana). The sections were placed in phosphate-buffered saline solution (PBS) and processed with reagent containing 3, 3’, 5, 5’- tetramethylbenzidine (TMB), liquid substrate for ELISA (Sigma, Milan), by the method reported above. On the spectrophotometer reading, values of 0.88 were obtained in case A and 1.63 in case B. The histological sections, after washing in PBS, were immersed in acid solution (0.01N HC1, pH 2.2) for 10 min. at room temperature, then washed again in PBS and processed immunohistochemically in a Ventana apparatus as specified above. The sections were treated with double-stranded DNA monoclonal mouse antibody (Double Stranded DNA Monoclonal Antibody (AE-2)), then with reagent designed to detect mouse immunoglobulins (Ultraview detection kit, Ventana). The sections, collected in PBS, were treated as above with TMB, to measure the amount of peroxidase and therefore, indirectly, the amount of dsDNA (i.e. the total nuclei present in the sections, as an indicator of the cells present). After the reaction, the TMB reagent was processed for reading on the spectrophotometer. We obtained the following values: Case A = 3.28; Case B= 3.15. These values indicate that although the sections had almost identical dimensions, the number of nuclei present was different. By calculating Ki67 value / DNA value x 100, the following results were obtained: case A: 0.88/ 3.28 x 100 = 26.8; case B: 1.63/ 3.15 x 100 = 51.7. The data indicate the possibility of obtaining a numerical evaluation (index) of the expression of antigen Ki67, which clearly differs in low-proliferation and high-proliferation tumours.
Example 3
Tissue cancers are currently tested for expression of PD-L1 (Programmed Death- Ligand 1) in order to devise the therapeutic approach. It has been observed that in immune “checkpoints” PD1-PDL1 there is a mechanism that blocks the immune response, and that expression of PD-L1 is correlated with immune evasion by tumour tissues. Treatment with anti-PD-Ll antibodies can have the effect of controlling tumour
growth in tumours that express said marker, and the therapeutic effect observed is correlated with the intensity of expression. PD-L1 is therefore tested for in histological sections, using immunohistochemical methods. The evaluation of intensity of expression is reported as the percentage of positive cells.
Currently, testing for PD-L1 expression is performed in numerous types of tumours, especially lung cancers and malignant melanomas (Scheel et al., 2016; Sunshine et al., 2017). If the percentage measurement method relating to marker PD-L1 is to be used, it is essential to identify the reference marker, expressed in all tumour cells. Said marker can be identified with cytokeratin in the case of carcinoma, whereas in the case of melanoma, protein SI 00 is preferred.
Two cases of malignant skin melanoma were selected. Sections of said cases (fragments of tumour tissue, after fixing in buffered formalin and embedding in paraffin) were stained with anti-PD-Ll antibody (SP263). In said immunohistochemical reaction the number of tumour cells positive for PD-L1 on the cell surface is taken as the reference number. The number of positive PD-L1 cells (optical evaluation) was 3% for case A and 30% for case B. Sections of the two cases were processed immunohistochemically, after paraffin removal, using a Ventana automated apparatus (Ventana BenchMark AutoStainer, Ventana Medical Systems, USA). After antigen retrieval treatment with Cell Conditioning 1 (CC1, slightly basic; Ventana) for 36 minutes at 95°C, the sections were incubated with anti-PD-Ll (SP263) antibody (Roche). After washing, the sections were treated with peroxidase-labelled anti-immunoglobulin antibody (Ultraview detection kit, Ventana). The sections were placed in phosphate-buffered saline solution (PBS) and processed with reagent containing 3, 3’, 5, 5’- tetramethylbenzidine (TMB), liquid substrate for ELISA (Sigma, Milan), by the method reported above. On the spectrophotometer reading, values of 0.55 were obtained in case A and 1.54 in case B. The histological sections, after washing in PBS, were immersed in acid solution (0.01N HC1, pH 2.2) for 10 min. at room temperature, then washed again in PBS and processed immunohistochemically in a Ventana apparatus as specified above. The sections were
treated with anti-S-100 protein antibody, then with a reagent designed to detect immunoglobulins (Ultraview detection kit, Ventana). The sections, collected in PBS, were treated as above with TMB, to measure the amount of peroxidase and therefore, indirectly, the amount of S-100 protein as an indicator of the cells present. After the reaction, the TMB reagent was processed for reading on the spectrophotometer. The following mean values were obtained: Case A = 3.25; Case B= 3.10. These values indicate that although the sections had almost identical dimensions, the number of cellspresent was different. By calculating PD-L1 value / S100 value x 100, the following results were obtained: Case A: 0.55/ 3.25 x 100 = 16.9. Case B: 1.54/ 3.10 x 100 = 49.6.
The data indicate the possibility obtaining a numerical valuation (index) of the expression of antigen Pd-Ll, which clearly differs in low-expressing and high-expressing tumours, which are therefore more likely to respond to targeted treatment.
Bibliography
Taylor CR et al., Quantification of immunohistochemistry - issues concerning methods, utility and semi quantitative assessment II. Histopathology 2006, 49, 411-424.
Taylor CR Predictive Biomarkers and Companion Diagnostics. The Future of Immunohistochemistry - ‘in situ proteomics’, or just a ‘stain’? Appl Immunohistochem Mol Morphol. 2014 September; 22(8): 555-561.
Laurinavicius A et al., Comprehensive Immunohistochemistry: Digital, Analytical and Integrated. Pathobiology 2016; 83: 156-163.
Grube D. Constants and variables in immunohistochemistry. Arch. Histol. Cytol. 2004, 67, 115-134.
Taylor CR. An exaltation of experts; concerted efforts in the standardization of immunohistochemistry. Appl. Immunohistochem. 1993; 1; 232-243.
Taylor CR. Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. Biotechnic. Histochem. 2006; 81; 3-12.
Becker RL. Standardization and quality control of quantitative microscopy in pathology. J. Cell. Biochem. 1993; 17G; 199-204.
Seidal T et al., Interpretation and quantification of immunostains. Am. J. Surg. Pathol. 2001; 25; 1204-1207.
Hatanaka Y et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis. Pathol. Int. 2001; 51; 33-36.
Rhodes A et al., Evaluation of Her24ieu immunohistochemical assays sensitivity and scoring on formalin- fixed and paraffin-processed cell lines and breast tumours: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 2002; 118; 408-417.
Lehr HA et al., Quantitative evaluation of HER-24ieu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.
Am. J. Clin. Pathol. 2001; 115; 814-822.
Cross SS. Observer accuracy in estimating proportions in images: implications for the semi quantitative assessment of staining reactions and a proposal for a new system. J. Clin. Pathol. 2001; 54; 385-390. Di Cataldo S et al., Computer-aided Techniques for Chromogenic
Immunohistochemistry: Status and Directions. Comput Biol Med., 2012;42: 1012-25.
Sunshine J.C. et al., PD-L1 Expression in Melanoma: A Quantitative.
Immunohistochemical Antibody Comparison. Clin Cancer Res; 23(16); 4938-44, 2017. Scheel A.H. et al., PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology (2016) 29, 116.
Claims
1. A method of quantitative immunohistochemical determination of tissue antigens which comprises: a) Placing the histological preparation in contact with an anti-tissue antigen antibody of diagnostic interest and then with an anti-antibody antibody labelled with an enzyme specific for a substrate detectable by colorimetry; b) Developing the preparation with a substrate which gives rise to a soluble product that can be determined by spectrophotometry, and reading of a first signal X; c) Removing the anti-tissue antigen and anti-antibody antibodies by washing; d) Placing the washed preparation in contact with a second anti-epithelial cell marker antibody and then with an anti-antibody antibody labelled with an enzyme specific for a substrate detectable by colorimetry; e) Developing the preparation with a substrate which gives rise to a product that can be determined by spectrophotometry, and reading of a second signal Y; f) Determining index X / Y x 100.
2. Method according to claim 1 wherein the specific enzyme for a substrate detectable by colorimetry is a peroxidase.
3. Method according to claim 2 wherein the peroxidase is horseradish peroxidase.
4. Method according to claim 2 or 3 wherein the peroxidase soluble substrate is selected from tetramethylbenzidine, 2,2'-azino-di[3-ethylbenzothiazoline] sulphonate and o-phenylenediamine.
5. Method according to claim 1 or 2 wherein the tissue antigens are tumour antigens.
6. Method according to claim 5 wherein the tumour antigens are HER2, Ki67 or PD- L1 antigens.
7. Method according to any one of claims 1 to 6 wherein the cell marker is cytokeratin, Epithelial Membrane Antigen or dsDNA.
8. Method according to one or more of claims 1 to 7 characterised in that glass or plastic trays with a width of 25 to 27 mm, length of 75 to 78 mm and height of 1 to 5 mm are used.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000030365 | 2020-12-10 | ||
IT102020000030365A IT202000030365A1 (en) | 2020-12-10 | 2020-12-10 | METHOD OF QUANTITATIVE IMMUNOHISTOCHEMICAL DETERMINATION OF ANTIGENS |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022123505A1 true WO2022123505A1 (en) | 2022-06-16 |
Family
ID=74759339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/061547 WO2022123505A1 (en) | 2020-12-10 | 2021-12-10 | Quantitative immunohistochemical antigen determination method |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT202000030365A1 (en) |
WO (1) | WO2022123505A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008005464A2 (en) * | 2006-06-30 | 2008-01-10 | University Of Southern California | Quantifiable internal reference standards for immunohistochemistry and uses thereof |
WO2008023055A1 (en) * | 2006-08-25 | 2008-02-28 | Universite Catholique De Louvain | Method and kit for determining antigen content in a sample using double immunohistochemical detection |
WO2010066252A1 (en) * | 2008-12-09 | 2010-06-17 | Dako Denmark A/S | Method for evaluating pre-treatment |
-
2020
- 2020-12-10 IT IT102020000030365A patent/IT202000030365A1/en unknown
-
2021
- 2021-12-10 WO PCT/IB2021/061547 patent/WO2022123505A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008005464A2 (en) * | 2006-06-30 | 2008-01-10 | University Of Southern California | Quantifiable internal reference standards for immunohistochemistry and uses thereof |
WO2008023055A1 (en) * | 2006-08-25 | 2008-02-28 | Universite Catholique De Louvain | Method and kit for determining antigen content in a sample using double immunohistochemical detection |
WO2010066252A1 (en) * | 2008-12-09 | 2010-06-17 | Dako Denmark A/S | Method for evaluating pre-treatment |
Non-Patent Citations (4)
Title |
---|
BATTIFORA H: "ASSESSMENT OF ANTIGEN DAMAGE IN IMMUNOHISTOCHEMISTRY THE VIMENTIN INTERNAL CONTROL", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, AMERICAN SOCIETY FOR CLINICAL PATHOLOGY, US, vol. 96, no. 5, 1 January 1991 (1991-01-01), pages 669 - 671, XP009126458, ISSN: 0002-9173 * |
GEORGE GLASS ET AL: "Simple: A Sequential Immunoperoxidase Labeling and Erasing Method", JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 57, no. 10, 13 April 2009 (2009-04-13), US, pages 899 - 905, XP055676909, ISSN: 0022-1554, DOI: 10.1369/jhc.2009.953612 * |
TAYLOR CLIVE R: "Quantifiable internal reference standards for immunohistochemistry - The measurement of quantity by weight", APPLIED IMMUNOHISTOCHEMISTRY, LIPPINCOTT WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, vol. 14, no. 3, 1 September 2006 (2006-09-01), pages 253 - 259, XP009126403, ISSN: 1062-3345 * |
WEI CHANG COLIN TAN ET AL: "Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy", CANCER COMMUNICATIONS, vol. 40, no. 4, 1 April 2020 (2020-04-01), pages 135 - 153, XP055710880, ISSN: 2523-3548, DOI: 10.1002/cac2.12023 * |
Also Published As
Publication number | Publication date |
---|---|
IT202000030365A1 (en) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110111435A1 (en) | Detecting Cell Surface Markers | |
Holten-Rossing et al. | Optimizing HER2 assessment in breast cancer: application of automated image analysis | |
US20190219579A1 (en) | Methods and systems for scoring extracellular matrix biomarkers in tumor samples | |
WO2014100220A2 (en) | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer | |
WO2010033597A2 (en) | Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same | |
EP1604184A2 (en) | Standardized evaluation of therapeutic efficacy based on cellular biomarkers | |
US9097618B2 (en) | Method for preparing cell standard | |
Rao et al. | Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides | |
Jonmarker Jaraj et al. | Intra-and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer | |
EP2664921A1 (en) | Assay | |
KR20190045200A (en) | Keratin 17 as a biomarker for bladder cancer | |
WO2022123505A1 (en) | Quantitative immunohistochemical antigen determination method | |
Innaro et al. | Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology | |
AU2010339478B2 (en) | Simultaneous detection of mutational status and gene copy number | |
CN114660289A (en) | Liver cancer marker and application thereof | |
Serrero et al. | Immunohistochemical detection of progranulin (PGRN/GP88/GEP) in tumor tissues as a cancer prognostic biomarker | |
US8252542B2 (en) | Serpin B 13 as a marker for squamous cell carcinoma of the lung | |
KR102260250B1 (en) | Biomarker, kit or composition for detecting cancer caused by inhibition of transcriptional activity of p53, method for providing information or screening drugs, and malignant transformation model | |
CN113671187A (en) | IHC detection kit for detecting MYCN protein | |
CN108474025A (en) | Using more Phenotype typings of fluorescent quenching successively and the biological sample dyed again | |
Cintrón et al. | Automated TTF-1 Immunohistochemistry Assay for the Differentiation of Lung Adenocarcinoma Versus Lung Squamous Cell Carcinoma | |
EP1354210B1 (en) | Method for cancer diagnostics | |
US20140113385A1 (en) | Compositions and Methods for Identifying Single Antigens or Other Molecules in Cell Preparations | |
CN117147844A (en) | Tumor cell subset and application thereof as colorectal cancer diagnosis marker | |
US20140274773A1 (en) | Systems and methods for employing podocalyxin and tra human stem cell markers as prognostic markers for aggressive and metastatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21839668 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21839668 Country of ref document: EP Kind code of ref document: A1 |